Abstract
Syngeneic graft-versus-host disease (SGVHD), a chronic inflammatory disease, develops following irradiation, syngeneic bone marrow transplantation (BMT) and treatment with the immunosuppressive agent cyclosporine A (CsA). We have shown that TH1 and TH17 cytokine responses are increased during the development of SGVHD. The current study was designed to further investigate the involvement of TH17 immunity in SGVHD-associated colitis. IL-23 is a TH17 cytokine responsible for maintaining the effector functions of TH17 cells. The administration of anti-mouse IL-23p19 was shown to significantly reduce the clinical symptoms of primary and secondary SGVHD-associated colitis resulting in a significant reduction in both TH1 and TH17 associated cytokine expression. These results demonstrate that the TH17-associated cytokine, IL-23, may prove to be a beneficial therapeutic target in the treatment of chronic colon inflammation.
Original language | English |
---|---|
Pages (from-to) | 732-735 |
Number of pages | 4 |
Journal | Cytokine |
Volume | 61 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2013 |
Keywords
- CD4 T cells
- Cyclosporine A
- Interleukin-23
- Mucosal inflammation
- Transplantation
ASJC Scopus subject areas
- Molecular Biology
- Hematology
- Biochemistry
- Immunology and Allergy
- Immunology